219 related articles for article (PubMed ID: 23226334)
21. Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.
Richard SD; Bencherif B; Edwards RP; Elishaev E; Krivak TC; Mountz JM; DeLoia JA
Nucl Med Biol; 2011 May; 38(4):485-91. PubMed ID: 21531285
[TBL] [Abstract][Full Text] [Related]
22. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
[TBL] [Abstract][Full Text] [Related]
23. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
24. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET.
Fuchs K; Kohlhofer U; Quintanilla-Martinez L; Lamparter D; Kötter I; Reischl G; Röcken M; Pichler BJ; Kneilling M
J Nucl Med; 2013 Jan; 54(1):151-8. PubMed ID: 23213198
[TBL] [Abstract][Full Text] [Related]
25. Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using
Heinzmann K; Nguyen QD; Honess D; Smith DM; Stribbling S; Brickute D; Barnes C; Griffiths J; Aboagye E
J Nucl Med; 2018 Oct; 59(10):1558-1565. PubMed ID: 29794225
[TBL] [Abstract][Full Text] [Related]
26. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
[TBL] [Abstract][Full Text] [Related]
27. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
[TBL] [Abstract][Full Text] [Related]
28. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H
Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
[TBL] [Abstract][Full Text] [Related]
30. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
[TBL] [Abstract][Full Text] [Related]
31. Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation.
Lin C; Kume K; Mori T; Martinez ME; Okazawa H; Kiyono Y
J Nucl Med; 2015 Jun; 56(6):945-50. PubMed ID: 25766892
[TBL] [Abstract][Full Text] [Related]
32. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
33. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
[TBL] [Abstract][Full Text] [Related]
34. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
35. Monitoring the early biologic response of esophageal carcinoma after irradiation with 18F-FLT: an in-vitro and in-vivo study.
Jiang M; Huang Q; Chen P; Ruan X; Luo Z; Zhao L; Fan W; Peng T; Sun L; Wu H
Nucl Med Commun; 2014 Dec; 35(12):1212-9. PubMed ID: 25192190
[TBL] [Abstract][Full Text] [Related]
36. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).
Molthoff CF; Klabbers BM; Berkhof J; Felten JT; van Gelder M; Windhorst AD; Slotman BJ; Lammertsma AA
Mol Imaging Biol; 2007; 9(6):340-7. PubMed ID: 17643202
[TBL] [Abstract][Full Text] [Related]
37. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
38. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1339-47. PubMed ID: 17333178
[TBL] [Abstract][Full Text] [Related]
39. Prediction of tumor biological characteristics in different colorectal cancer liver metastasis animal models using
Xu HL; Li M; Zhang RJ; Jiang HJ; Zhang MY; Li X; Wang YQ; Pan WB
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):140-148. PubMed ID: 29571649
[TBL] [Abstract][Full Text] [Related]
40. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
